Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

HIV Clinical Trials

Volumn 4, Issue 2, 2003, Pages 115-120

  Martín Carbonero, Luz ^a   Núñez, Marina ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Efavirenz; Hepatitis C; Hepatotoxicity; HIV; Liver; Nevirapine

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LIVER; LIVER DISEASES; MALE; NEVIRAPINE; OXAZINES; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 0037356401     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/N4VT-3E9U-4BKN-CRPW     Document Type: Article

References (21)

1. Sulkowski M, Thomas D, Chaisson R, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
2. Brinker M, Wit F, Wertheim-van Killen P, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
3. Savès M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. AIDS. 1999;13:F115-F121.
4. D'Arminio A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J AIDS. 2001;28:114-123.
5. Gisolf E, Dreezen C, Danner S, et al. Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 2000;31:1234-1239.
6. Reisler R, Liou S, Servoss J, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 43.
7. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS. 2000;14(suppl 4):S12.
8. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997-2000. JAMA. 2001;285:402-403.
9. Martínez E, Blanco J, Arnaiz A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
10. Nuñez M, Lana R, Mendoza J, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J AIDS. 2001;27:426-431.
11. Piroth L, Grappin M, Segro C, et al. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV coinfected patients. Ann Pharmacother. 2000;34:534-535.
12. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
13. Puoti M, Patroni A, Pan L, et al. Hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors in 427 adults infected with HIV. In: Program and abstracts of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens. Abstract 129.
14. Sulkowski M, Mehta S, Thomas D, et al. Hepatotoxicity associated with NNRTI use: role of drugs and chronic viral hepatitis. In: Program and abstracts of the Eighth Conference of Retroviruses and Opportunistic Infections; February 2001; Chicago, Illinois. Abstract 618.
15. Arnaiz J, Martinez E, Cruceta A, et al. Efavirenz-associated liver toxicity: a prospective cohort study. In: Program and abstracts of the Eighth Conference of Retroviruses and Opportunistic Infections; October 2001; Athens. Abstract 130.
16. Dieterich D, Stern J, Robinson P, et al. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B & C seropositivity, and baseline liver function tests. In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 44.
17. Bennet C, Johnson S, Lynch P, et al. Hepatic and cutaneous toxicity attributed to nevirapine (NVP). In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 45.
18. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine-associated exhantema using slow dose scalation and/or corticosteroids. AIDS. 2000;14:2153-2157.
19. Torriani F, Soriano V. Chronic hepatitis C in HIV-infected individuals. AIDS Rev. 2000;2:168-177.
20. Pérez-Olmeda M, Núñez M, Romero M, et al. Pegylated interferon alpha-2b plus ribavirin as therapy for HIV-infected patients with chronic hepatitis C. AIDS. In press.
21. González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V. Liver toxicity due to